trientine has been researched along with Cancer of Ovary in 3 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, DP | 1 |
| Chin-Sinex, H | 1 |
| Nie, B | 1 |
| Mendonca, MS | 1 |
| Wang, M | 1 |
| Fu, S | 1 |
| Naing, A | 1 |
| Fu, C | 1 |
| Kuo, MT | 1 |
| Kurzrock, R | 1 |
| Yellepeddi, VK | 1 |
| Vangara, KK | 1 |
| Kumar, A | 1 |
| Palakurthi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies[NCT01178112] | Phase 1 | 56 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for trientine and Cancer of Ovary
| Article | Year |
|---|---|
Overcoming platinum resistance through the use of a copper-lowering agent.
Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cation Transport Proteins; | 2012 |
2 other studies available for trientine and Cancer of Ovary
| Article | Year |
|---|---|
Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Chelating | 2009 |
Comparative evaluation of small-molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Cell Line, Tumor; C | 2012 |